ID
4716
Description
see http://clinicaltrials.gov/ct2/show/record/NCT00617669 Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
Link
http://clinicaltrials.gov/ct2/show/record/NCT00617669
Keywords
Versions (6)
- 11/15/11 11/15/11 -
- 3/23/14 3/23/14 - Martin Dugas
- 8/10/14 8/10/14 - Martin Dugas
- 4/13/21 4/13/21 - Dr. rer. medic Philipp Neuhaus
- 9/20/21 9/20/21 -
- 9/28/21 9/28/21 - Sarah Riepenhausen
Uploaded on
March 23, 2014
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0 Legacy
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility NCT00617669 Prostate Cancer
Eligibility NCT00617669
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI-1
- C0680251
Description
Previous chemotherapy
Data type
boolean
Alias
- UMLS CUI-1
- C0205156
- UMLS CUI-2
- C0392920
Description
Heart disease
Data type
boolean
Alias
- UMLS CUI-1
- C0018801
- UMLS CUI-2
- C0155626
Description
Epilepsy, seizures
Data type
boolean
Alias
- UMLS CUI-1
- C0014544
- UMLS CUI-2
- C0036572
Similar models
Eligibility NCT00617669
- StudyEvent: Eligibility
C0153690 (UMLS CUI-2)
C0392920 (UMLS CUI-2)
C0155626 (UMLS CUI-2)
C0036572 (UMLS CUI-2)